Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213289 · ClinicalTrials.gov registry record · Phase 2
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02213289 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 80 participants.
The verdict
NCT02213289, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.
Interventions
- DRUG Trastuzumab
- DRUG Nivolumab
- DRUG Ramucirumab
- DRUG Bemarituzumab
- DRUG ABT-806
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-01-20 |
| Est. Completion | 2020-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02213289
The ClinicalTrials.gov registry entry for NCT02213289 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT02213289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02213289 about?
NCT02213289 is a clinical study titled "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression". The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects...
What is the current status of trial NCT02213289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2015-01-20. Estimated completion is 2020-08-20.
What interventions are being tested in trial NCT02213289?
The interventions under investigation include: Trastuzumab (DRUG), Nivolumab (DRUG), Ramucirumab (DRUG), Bemarituzumab (DRUG), ABT-806 (DRUG).
Who is sponsoring clinical trial NCT02213289?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.